Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810061 | 1.00 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1F2PRSS1 | |
| SCHEMBL31702015 | 1.00 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1F2PRSS1 | |
| SCHEMBL24541901 | 1.00 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1F2PRSS1 | |
| SCHEMBL24541928 | 0.87 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1F2PRSS1 | |
| SCHEMBL3232763 | 0.79 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1ALDH1A1CASP1 | |
| SCHEMBL7646219 | 0.79 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1ALDH1A1CASP1 | |
| SCHEMBL14455227 | 0.79 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1ALDH1A1CASP1 | |
| SCHEMBL7526406 | 0.79 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1ALDH1A1CASP1 | |
| SCHEMBL810894 | 0.79 | PTGES2 (0.48) | SLC1A3SLC1A2SLC1A1PGRACLY | |
| SCHEMBL7613315 | 0.78 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1223998-A | Process for producing trans- (R, R) -actinol | HOFFMANN LA ROCHE (CH) | 1999-07-28 | — | — | CN | claimed |
| WO-2022127321-A1 | NOVEL INTERMEDIATE, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | 四川大学 | 2022-06-23 | — | — | WO | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-7834190-B2 | Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof | KANEKA CORPORATION (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100048909-A1 | Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof | KANEKA CORPORATION | 2010-02-25 | — | — | US | disclosed |
| EP-2039689-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-2 -HYDROXYPROPIONIC CYCLOPROPYLAMIDE DERIVATIVES AND SALTS THEREOF | Kaneka Corporation (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| CN-1223998-A | Process for producing trans- (R, R) -actinol | HOFFMANN LA ROCHE (CH) | 1999-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048909-A1 | Process for production of optically active-3-amino-2-hydroxypropionic cyclopropylamide derivatives and salts thereof | HPD, HAAO, OGFOD1 | SLC1A3 736/4885SLC1A2 320/4885SLC1A1 475/4885 |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | SLC1A3 1322/4885SLC1A2 1122/4885SLC1A1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.